Explore the Potential with AI-Driven Innovation
The specialised, focused library is developed on demand with the most recent virtual screening and parameter assessment technology, guided by the Receptor.AI drug discovery platform. This approach exceeds the capabilities of traditional methods and offers compounds with higher activity, selectivity, and safety.
We carefully select specific compounds from a vast collection of over 60 billion molecules in virtual chemical space. Our partner Reaxense helps in synthesizing and delivering these compounds.
The library includes a list of the most effective modulators, each annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Furthermore, each compound is shown with its optimal docking poses, affinity scores, and activity scores, offering a detailed summary.
We use our state-of-the-art dedicated workflow for designing focused libraries.
Fig. 1. The sreening workflow of Receptor.AI
Our methodology employs molecular simulations to explore a wide array of proteins, capturing their dynamic states both individually and within complexes. Through ensemble virtual screening, we address conformational mobility, uncovering binding sites within functional regions and remote allosteric locations. This thorough exploration ensures no potential mechanism of action is overlooked, aiming to discover novel therapeutic targets and lead compounds across an extensive spectrum of biological functions.
Our library is unique due to several crucial aspects:
partner
Reaxense
upacc
Q9UBF9
UPID:
MYOTI_HUMAN
Alternative names:
57 kDa cytoskeletal protein; Myofibrillar titin-like Ig domains protein; Titin immunoglobulin domain protein
Alternative UPACC:
Q9UBF9; A0A4R6; B4DT79
Background:
Myotilin, a 57 kDa cytoskeletal protein, plays a pivotal role in muscle cell structure and function. It is a key component of a complex of actin cross-linking proteins, crucial for myofibril assembly and stability at the Z lines in muscle cells. Myotilin's alternative names include Myofibrillar titin-like Ig domains protein and Titin immunoglobulin domain protein.
Therapeutic significance:
Myotilin is implicated in Myopathy, myofibrillar, 3 (MFM3), a neuromuscular disorder characterized by progressive skeletal muscle weakness and cardiomyopathy. Understanding the role of Myotilin could open doors to potential therapeutic strategies for treating MFM3 and related muscular disorders.